OBJECTIVES: To estimate the number of patients receiving Allogeneic Stem Cell Transplant (ASCT) and presenting with graft versus host disease (GVHD) in 2012 in France. METHODS: French hospital databases named PMSI record medical information about all the hospitalizations performed annually in France. From 2006 to 2012, databases allow linking the stays of a given patient over time with an anonymous number. In this study, PMSI databases were used to identify patient, aged more than 15, with allogeneic stem cell transplant through adequate Diagnosis Related Group and who were alive, hospitalized during the year 2012. Patients with diagnosis of GVHD or typical diagnoses of GVHD symptoms (sclerodermia, diarrhea, mucitis and keratitis) were identified. RESULTS: Since 2006 to 2012, 9,855 patients received allogeneic stem cell transplant in France of which 3,469 died during a hospitalization over the period, with an annual death rate stable around 20%. In 2012, 3,842 ASCT patients aged more than 15 were hospitalized at least once, and the proportion with GVHD was estimated to 40% (1,574). Acute GVHD diagnosis or typical GVHD symptoms occurring less than 100 days after grafting appeared in 274 patients and chronic GVHD was diagnosed in 1300 patients. Mean age was 47.8, 61.4% were male and 22% of these patients died during a stay in 2012. Among the ASCT patients hospitalized in 2012, only 5% were grafted in 2006 and this figure regularly increased with the year of the procedure to reach 35% grafted in 2012, corresponding to a mean annual mortality rate of around 20%.  CONCLUSIONS: Among the 3,842 ASCT patients hospitalized in France in 2012, 1,574 (40%) presented GVHD, putting them at higher risk of immunosuppression and invasive fungal infection, but also at higher risk of death.